Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Effect of Curcumin as Nutraceutical in Patients of Depression
- Conditions
- Interventions
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Government Medical College, Bhavnagar
- Target Recruit Count
- 60
- Registration Number
- NCT01022632
- Locations
- 🇮🇳
Sir Takthasinhji General Hospital, Bhavnagar, Gujarat, India
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 2
- Registration Number
- NCT00986310
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Donaghue Medical Research Foundation
- Target Recruit Count
- 49
- Registration Number
- NCT00965562
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
A Study in Relapse Prevention of Treatment-Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 892
- Registration Number
- NCT00958568
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sisli, Turkey
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 134
- Registration Number
- NCT00958204
- Locations
- 🇨🇦
UBC Hospital Mood Disorders Centre, Vancouver, British Columbia, Canada
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT00942708
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Brain Imaging Techniques That Predict Antidepressant Responsiveness
- Conditions
- Interventions
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 50
- Registration Number
- NCT00909155
- Locations
- 🇺🇸
University of Wisconsin Madison Psychiatry Department, Madison, Wisconsin, United States
Fluoxetine Essay in Children With Autism
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Registration Number
- NCT00873834
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT00849693
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 337
- Registration Number
- NCT00849901
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.